Regulatory Roundup: EMA and the European Monitoring Center for Drugs to Cooperate; And More. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: EMA and the European Monitoring Center for Drugs to Cooperate; And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency (EMA) and the European Monitoring Centre for Drugs and Drug Addiction agreed to a working arrangment on June 14, 2010, as part of EMA’s initiative to “cooperate with other European Union bodies for early identification and management of potential conflicts over scientific opinions,” according to an agency press release. The agreement includes fostering cooperation between the two agencies, including sharing information and reports on new psychoactive substances and any misuse of these products.

 

According to various Chinese media reports, on June 13, 2010, the deputy head of the China State Food and Drug Administration (SFDA), Zhang Jingli, was fired for disciplinary violations. In 2007, the then SFDA Chief Zheng Xiaoyu was executed after an investigation showed that he approved unsafe drugs, which ultimately led to the deaths of some consumers, in exchange for money. An investigation on Zhang is being conducted.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here